Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110706 · ClinicalTrials.gov registry record · Phase 2
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
A Phase 2 study of Myasthenia Gravis, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT02110706 is a Phase 2 study of Myasthenia Gravis that has completed, run by Yale University. The registered enrollment target is 52 participants, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02110706, a Phase 2 study of Myasthenia Gravis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rituximab
Study Locations (20)
New York
- SUNY Downstate Medical Center - Brooklyn
- SUNY Buffalo - Buffalo
- Columbia University Medical Center - New York
- Weill Cornell Medical Center - New York
- University of Rochester - Rochester
- SUNY Stony Brook - Stony Brook
- Montefiore Medical Center - The Bronx
California
- University of California - Davis - Davis
- University of California - Los Angeles - Los Angeles
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Denver - Denver
Connecticut
- Yale School of Medicine, Department of Neurology - New Haven
Florida
- University of Miami School of Medicine - Miami
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110706
The ClinicalTrials.gov registry entry for NCT02110706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (73% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02110706 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02110706 about?
NCT02110706 is a clinical study titled "BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis". The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
What is the current status of trial NCT02110706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2014-05. Estimated completion is 2018-05.
What conditions does trial NCT02110706 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT02110706?
The interventions under investigation include: Placebo (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT02110706?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02110706 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.